Saturday, May 21, 2016 3:34:18 PM
Recent KALV News
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 11/05/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 09:40:30 PM
- KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million • Business Wire • 11/04/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 12:00:58 PM
- KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust • Business Wire • 11/04/2024 12:00:00 PM
- KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology • Business Wire • 10/28/2024 10:30:00 AM
- KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) • Business Wire • 10/18/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 08:08:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 08:07:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 08:07:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 08:05:46 PM
- KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum • Business Wire • 10/04/2024 04:29:00 PM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 10/02/2024 10:30:00 AM
- KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema • Business Wire • 09/30/2024 10:30:00 AM
- KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) • Business Wire • 09/26/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 08:34:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 08:32:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 12:31:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 08:39:55 PM
- KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 11:00:00 AM
- KalVista Appoints Brian Piekos as Chief Financial Officer • Business Wire • 09/10/2024 10:30:00 AM
- KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 • Business Wire • 09/06/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:24:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/05/2024 08:07:47 PM
- KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update • Business Wire • 09/05/2024 10:30:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM